Key result
A negative B natriuretic peptide or NTProBNP test, when combined with a clinical risk scoring system, identifies normotensive patients with confirmed pulmonary embolism at negligible risk of complications.
Why the study?
Does negative B natriuretic peptide testing identify patients with confirmed pulmonary embolism at low risk for a complicated clinical course?
Does negative B natriuretic peptide testing identify patients with confirmed pulmonary embolism at low risk for a complicated clinical course?
Answers are grounded in this paper and cite their sources.
Negative BNP or NT-proBNP testing, especially when combined with clinical risk scores, identifies normotensive pulmonary embolism patients at negligible risk of complications who may be suitable for outpatient therapy.
A shortcut review was carried out to establish whether a negative B natriuretic peptide could identify patients with confirmed pulmonary embolus at low risk for a complicated clinical course and therefore potentially suitable for outpatient therapy. Two systematic review/meta-analyses were found directly relevant to the three-part question. A further six prospective cohort studies of high quality postdating the systematic review were also found, relevant to the three-part question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are tabulated. The clinical bottom line is that in normotensive patients with confirmed pulmonary embolism, a negative B natriuretic peptide or NTProBNP confers a low clinical risk of complications. When used in addition to a clinical risk scoring system such as the simplified pulmonary severity index, the risk becomes negligible (<1%). Such patients could be considered for outpatient therapy direct from the emergency department.
No takes yet. Share an insight, caveat, or question.
Ferguson et al. (2015) conducted a review in Pulmonary embolus. Negative B natriuretic peptide or NTProBNP testing was evaluated on Complicated clinical course. A negative B natriuretic peptide or NTProBNP test, when combined with a clinical risk scoring system, identifies normotensive patients with confirmed pulmonary embolism at negligible risk of complications.
Synapse has enriched 10 related papers. Consider them for comparative context: